Literature DB >> 10896246

Plasma TAFI antigen variations in healthy subjects.

P Chetaille1, M C Alessi, D Kouassi, P E Morange, I Juhan-Vague.   

Abstract

The Thrombin Activatable Fibrinolysis Inhibitor (TAFI) is a recently described inhibitor of fibrinolysis. The physiological variations of plasma TAFI antigen are not well known. We studied TAFI antigen values in healthy populations with a commercially available kit from Milan Analytica (Switzerland). Broad range of TAFI antigen values (from 41% to 259%) was found in a population of 249 healthy individuals. Gender as well as pregnancy did not influence mean values of TAFI antigen. There was a positive correlation between TAFI antigen and age in female (r = 0.28; p <0.05) but not in male populations. Mean TAFI antigen value of a black African male group [mean +/- SD (range): 87 +/- 23 (39-144%)] was significantly lower than the one of age matched Caucasian men [114 +/- 34 (52-259%)] (p <0.0001). TAFI antigen values were very stable within individuals, they did not significantly vary on day time or at several months period. Thus, in contrast to large inter-individual variations, TAFI antigen levels are quite stable within individuals.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10896246

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  In vivo regulation of plasminogen function by plasma carboxypeptidase B.

Authors:  Carmen M Swaisgood; Detlef Schmitt; Dan Eaton; Edward F Plow
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

2.  Coagulation and prothrombotic state parameters: a clinical analysis during early pregnancy.

Authors:  H Chen; L Zhou; L Meng; M Liu; J Tan; L Gao; J Zhang
Journal:  Ir J Med Sci       Date:  2011-08-02       Impact factor: 1.568

3.  Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life.

Authors:  Mariko Nagashima; Zheng-Feng Yin; Lei Zhao; Kathy White; Yanhong Zhu; Nina Lasky; Meredith Halks-Miller; George J Broze; William P Fay; John Morser
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

Review 4.  Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women.

Authors:  Tatjana Elène Vogelvang; Marius Jan van der Mooren; Velja Mijatovic; Peter Kenemans
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  Thrombin activatable fibrinolysis inhibitor in preeclampsia and gestational hypertension throughout the gestation.

Authors:  Yinghong Zhang; Yu Hu; Tao Guo; Wenning Wei; Xiaoping Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-05-15

6.  Thrombin activatable fibrinolysis inhibitor : its role in slow coronary flow.

Authors:  M N Yildirim; Y Selcoki; S Uysal; A B Nacar; B Demircelik; H I Aydin; B Eryonucu
Journal:  Herz       Date:  2013-09-27       Impact factor: 1.443

Review 7.  Measuring fibrinolysis: from research to routine diagnostic assays.

Authors:  C Longstaff
Journal:  J Thromb Haemost       Date:  2018-02-17       Impact factor: 5.824

8.  A Genome-wide Study of Common and Rare Genetic Variants Associated with Circulating Thrombin Activatable Fibrinolysis Inhibitor.

Authors:  Tara M Stanne; Maja Olsson; Erik Lorentzen; Annie Pedersen; Anders Gummesson; Ann Gils; Katarina Jood; Gunnar Engström; Olle Melander; Paul J Declerck; Christina Jern
Journal:  Thromb Haemost       Date:  2018-01-29       Impact factor: 5.249

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.